OHDSI MEETINGS THIS WEEK
Patient-level prediction (eastern hemisphere) workgroup meeting - Wednesday 3pm Hong Kong timehttps://global.gotomeeting.com/join/972917661
Population-level estimation (western hemisphere) workgroup meeting - Thursday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M3T9BZV9RSB6YNDM8WDDZMI19D-D1JL
Hadoop working group meeting - Friday at 11am EThttp://cloudera.webex.com/meet/sdolley
ANNOUNCEMENTS
OHDSI F2F - Registration is now open for the OHDSI F2F to take place on March 17-18th at GeorgiaTech in Atlanta. Register here:http://www.ohdsi.org/events/2017-ohdsi-collaborator-face-to-face/
OHDSI F2F Hack-a-thon tracks - Join us on tomorrow’s OHDSI collaborator call to learn more about the our aims for the F2F meeting in March.https://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=96139.9309014125233215312
It always seems impossible until it’s done.
COMMUNITY PUBLICATIONS
New insights into highly potent tyrosinase inhibitors based on 3-heteroarylcoumarins: Anti-melanogenesis and antioxidant activities, and computational molecular modeling studies.
F Pintus, MJ Matos, S Vilar, G Hripcsak, C Varela, E Uriarte, L Santana, F Borges, R Medda, A Di Petrillo, B Era and A Fais,
Bioorganic & medicinal chemistry , 2017 03 01
Melanogenesis is a physiological pathway for the formation of melanin. Tyrosinase catalyzes the first step of this process and down-regulation of its activity is responsible for the inhibition of melanogenesis. The search for molecules capable of controlling hyperpigmentation is a trend topic in health and cosmetics. A series of heteroarylcoumarins have been synthesized and evaluated. Compounds 4 and 8 exhibited higher tyrosinase inhibitory activities (IC50=0.15 and 0.38μM, respectively), than the reference compound, kojic acid (IC50=17.9μM). Compound 4 acts as competitive, while compound 8 as uncompetitive inhibitor of mushroom tyrosinase. Furthermore, compounds 2 and 8 inhibited tyrosinase activity and melanin production in B16F10 cells. In addition, compounds 2-4 and 8 proved to have an interesting antioxidant profile in both ABTS and DPPH radicals scavenging assays. Docking experiments were carried out in order to study the interactions between these heteroarylcoumarins and mushroom tyrosinase.
Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database.
D Yoon, SS Sheen, S Lee, YJ Choi, RW Park and HS Lim,
Medicine , Nov 2016
Although concern regarding the increased risk for new-onset diabetes mellitus (NODM) after statin treatment has been raised, there has been a lack of evidence in real-world clinical practice, particularly in East Asians. We investigated whether statin use is associated with risk for NODM in Koreans. We conducted a retrospective cohort study using the clinical research database from electronic health records. The study cohort consisted of 8265 statin-exposed and 33,060 matched nonexposed patients between January 1996 and August 2013. Matching at a 1:4 ratio was performed using a propensity score based on age, gender, baseline glucose levels (mg/dL), and hypertension. The comparative risks for NODM with various statins (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin) were estimated by both statin exposure versus matched nonexposed and within-class comparisons. The incidence of NODM among the statin-exposed group (6.000 per 1000 patient-years [PY]) was higher than that of the nonexposed group (3.244 per 1000 PY). The hazard ratio (HR) of NODM after statin exposure was 1.872 (95% confidence interval [CI], 1.432-2.445). Male gender (HR, 1.944; 95% CI, 1.497-2.523), baseline glucose per mg/dL (HR, 1.014; 95% CI, 1.013-1.016), hypertension (HR, 2.232; 95% CI, 1.515-3.288), and thiazide use (HR, 1.337; 95% CI, 1.081-1.655) showed an increased risk for NODM, while angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker showed a decreased risk (HR, 0.774; 95% CI, 0.668-0.897). Atorvastatin-exposed patients showed a higher risk for NODM than their matched nonexposed counterparts (HR, 1.939; 95% CI, 1.278-2.943). However, the risk for NODM was not significantly different among statins in within-class comparisons. In conclusion, an increased risk for NODM was observed among statin users in a practical healthcare setting in Korea.
